To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks
0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate
to severe hidradenitis suppurativa.